Molecular Targets for Endometriosis Therapy: Where We Are and Where We Are Going?

Fabio Barra, Antonio Simone Laganà, Jvan Casarin, Casarin J, Fabio Ghezzi, Lorenzo Ferro Desideri, Carolina Scala, Scala C, Simone Ferrero
International journal of fertility & sterility · 2019 · vol. 13(2) , pp. 89–92 · doi:10.22074/ijfs.2019.5736 · PMID:31037916 · PMC6500084 · W3021327785
editorial OA: gold CC0 ⤵ 9 in-corpus citations
📄 Open PDF Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

Numerous investigational drugs targeting specific biological mechanisms for endometriosis have been proposed, with some hormonal treatments nearing clinical use, while others require extensive research to assess efficacy and tolerability.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

⚙ AI-generated deep summary by claude@2026-06, 2026-06-07 · read from full text ⓘ

This review discusses molecular targets proposed for endometriosis therapy and surveys where therapeutic target research stands and what directions are emerging, drawing on published mechanistic and preclinical evidence for various pathways implicated in disease. It synthesizes current understanding of multiple classes of targets rather than reporting original experiments, and it acknowledges the complexity and heterogeneity of the condition as a key challenge for translating molecular findings into effective treatments. The major caveat is that the evidence base spans different experimental models and stages of development, which limits straightforward conclusions about clinical efficacy. This paper is centrally about endometriosis — it focuses on molecular targets for endometriosis therapy and summarizes current progress and future directions.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

In conclusion, a high number of new investigational drugs targeting specific biological mechanisms have recently been proposed for treatment of endometriosis. Although the use of new hormonal treatments, such as GnRH-antagonists, is being deeply tested in the last clinical studies appearing relatively near to introduce into clinical practice, the majority of other innovative agents and targets have been tested only in vitro and in the animal model. Thus, more extensive research is mandatory to assess their efficacy and tolerability. In particular, only a minority of these drugs seems suitable for future investigations, considering the cornerstones of the endometriosis management, as well as possible side-effects and impact on quality of life.
Full text 1,571 characters · extracted from oa-html · click to expand
Molecular Targets for Endometriosis Therapy: Where We Are and Where We Are Going? Fabio Barra, Antonio Simone Laganà, Jvan Casarin, Fabio Ghezzi, Lorenzo Ferro Desideri, Carolina Scala, Simone Ferrero Affiliations Fabio Barra Academic Unit of Obstetrics and Gynecology, Ospedale Policlinico San Martino, Largo R. Benzi, Genoa, Italy;Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Ge Antonio Simone Laganà Department of Obstetrics and Gynecology, Filippo Del Ponte Hospital, University of Insubria, Varese, Italy Jvan Casarin Department of Obstetrics and Gynecology, Filippo Del Ponte Hospital, University of Insubria, Varese, Italy Fabio Ghezzi Department of Obstetrics and Gynecology, Filippo Del Ponte Hospital, University of Insubria, Varese, Italy Lorenzo Ferro Desideri Academic Unit of Obstetrics and Gynecology, Ospedale Policlinico San Martino, Largo R. Benzi, Genoa, Italy;Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Ge Carolina Scala Academic Unit of Obstetrics and Gynecology, Ospedale Policlinico San Martino, Largo R. Benzi, Genoa, Italy;Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Ge Simone Ferrero Academic Unit of Obstetrics and Gynecology, Ospedale Policlinico San Martino, Largo R. Benzi, Genoa, Italy;Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Ge

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-html ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (30)

Cited by (9)

Source provenance

europepmc
last seen: 2026-07-28T06:14:09.330459+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:22:48.502547+00:00
License: CC0 · commercial use OK